1. Home
  2. LTRN vs GDTC Comparison

LTRN vs GDTC Comparison

Compare LTRN & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$3.59

Market Cap

38.3M

Sector

Health Care

ML Signal

HOLD

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

HOLD

Current Price

$1.05

Market Cap

15.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTRN
GDTC
Founded
2013
2018
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.3M
15.5M
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
LTRN
GDTC
Price
$3.59
$1.05
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$25.00
N/A
AVG Volume (30 Days)
52.7K
38.4K
Earning Date
11-12-2025
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$573,193.00
Revenue This Year
N/A
$5.37
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
63.03
52 Week Low
$2.55
$0.89
52 Week High
$6.12
$3.68

Technical Indicators

Market Signals
Indicator
LTRN
GDTC
Relative Strength Index (RSI) 54.64 26.33
Support Level $3.22 $0.89
Resistance Level $3.56 $1.39
Average True Range (ATR) 0.22 0.14
MACD 0.04 -0.03
Stochastic Oscillator 95.71 18.92

Price Performance

Historical Comparison
LTRN
GDTC

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: